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T he Multicenter Automatic Defibrillator Implantation Trial with Cardiac Resynchronization Therapy (MADIT-CRT) showed the safety and effectiveness of cardiacresynchronization therapy (CRT) with a defibrillator (CRT-D) in patients with asymptomatic or mildly symptomatic heart failure, a reduced ejection fraction, and a prolonged QRS duration. 1 The study showed that treatment with CRT-D was associated with a 34% relative reduction in the risk of nonfatal heart-failure events or death from any cause, as compared with implantable cardioverterdefibrillator (ICD) therapy alone over a median follow-up period of 2.4 years. The benefit of CRT-D in the trial was primarily driven by a significant relative reduction of 41% in the risk of nonfatal heart-failure events 1 and was subsequently shown to be restricted to patients with an electrocardiographic (ECG) pattern showing left bundle-branch block. 2 Thus, questions regarding the ability of CRT to reduce mortality among patients with asymptomatic or mildly symptomatic heart failure remained unanswered. In the present study, we prospectively assessed the long-term outcome of the patients enrolled in MADIT-CRT.
ME THODS

STUDY POPULATION
The design, protocol, and results of MADIT-CRT have been published previously. 1, 3 Briefly, 1820 patients with ischemic cardiomyopathy (New York Heart Association [NYHA] functional class I or II) or nonischemic cardiomyopathy (NHYA functional class II only), a left ventricular ejection fraction of 30% or less, and a prolonged QRS duration (≥130 msec) were randomly assigned in a 3:2 ratio to receive CRT-D or ICD therapy. All eligible patients met the guideline criteria for ICD therapy. Of the 1820 patients who were enrolled in MADIT-CRT, 1271 (70%) were enrolled at 88 centers in the United States, and 549 (30%) were enrolled at 24 centers in Europe, Israel, and Canada.
DATA ACQUISITION AND PATIENT FOLLOW-UP
MADIT-CRT was carried out from December 22, 2004, through June 22, 2009. After the publication of the primary results, 1 post-trial follow-up was conducted for all 1691 surviving study participants until September 10, 2010 (phase 1 of the extended follow-up). After September 10, 2010, ongoing patient follow-up (phase 2) was conducted at the 48 U.S. centers that agreed to participate in the long-term follow-up requested by the Food and Drug Administration for patients enrolled in the United States (coordinated by the Heart Research Follow-up Program at the University of Rochester Medical Center, Rochester, New York) and at 23 of the 24 non-U.S. centers (coordinated by the Israeli Association for Cardiovascular Trials at Sheba Medical Center, Tel Hashomer, Israel), in volving a total of 854 patients. A total of 40 U.S. centers declined to participate in the phase 2 registry.
The clinical characteristics of the patients who enrolled and those who did not enroll in phase 2 of the post-trial follow-up are shown in Table S1 in the Supplementary Appendix, available with the full text of this article at NEJM.org. Both phases of the post-trial follow-up were approved by the institutional review board at each participating center, and all the patients provided written informed consent. The numbers of patients enrolled in the trial and in the post-trial followup phases are shown in Figure 1 .
All the authors were involved in the study design, data collection, and analysis; participated in the writing of the manuscript; and made the decision to submit the manuscript for publication. The commercial sponsor had no role in the study design, data accrual or analysis, or manuscript preparation or review. All the authors vouch for the accuracy and completeness of the reported findings and for the fidelity of the study to the protocol.
DEFINITIONS AND END POINTS
The original MADIT-CRT protocol did not specify the evaluation of a potential differential effect of CRT-D with respect to QRS morphologic findings at baseline (in other respects, the current report is true to the protocol). However, after the publication of the primary report, 1 analyses were performed comparing patients who had left bundle-branch block (70% of the study patients) with those who did not have left bundle-branch block (30%, including 13% with right bundle-branch block and 17% with an intraventricular conduction delay), which suggested that the reduced risk of the primary end point with CRT-D was largely, or even entirely, in the subgroup of patients with left bundle-branch block. 2 On the basis of this post-trial observation, the analysis in the present study evaluated the dif-3 ferential effects of CRT-D according to baseline QRS morphologic findings -specifically, left bundle-branch block or no left bundle-branch block. Two patients with missing data regarding QRS pattern at enrollment were excluded from the present study. Thus, the final study sample included the 1818 patients from MADIT-CRT for whom baseline ECG data were available.
The primary end point of the current study was death from any cause. Secondary end points included a nonfatal heart-failure event and the combined end point of a nonfatal heart-failure event or death, whichever occurred first.
STATISTICAL ANALYSIS
All analyses in the present study were carried out on an intention-to-treat basis (i.e., according to the original treatment assignment, regardless of intrial or post-trial crossovers). Variables were expressed as means ±SD, and categorical data were summarized as frequencies and percentages. The clinical characteristics of the patients at baseline were compared between the subgroups, with the use of the Kruskal-Wallis test for continuous variables and the chi-square test or Fisher's exact test for dichotomous variables.
The Kaplan-Meier method was used to determine cumulative probabilities of death from any cause and nonfatal heart-failure events from the time of enrollment in MADIT-CRT through posttrial follow-up, according to treatment group, with between-group comparisons of cumulative event rates calculated by means of the log-rank test. The number of patients who would need to be treated with CRT-D to save one life was calculated as the inverse of the survival difference between the two treatment groups at each time point.
Multivariate Cox proportional-hazards regression analyses were used to evaluate the effect of CRT-D on the two end points of death from any cause and a nonfatal heart-failure event and on the combined end point of a nonfatal heart-failure event or death (whichever came first), from the time of enrollment in MADIT-CRT through posttrial follow-up. The Cox model was adjusted for relevant clinical covariates with the use of bestsubset regression modeling (including age, serum creatinine level, presence or absence of diabetes mellitus, cause of cardiomyopathy, left ventricular end-systolic volume, QRS duration, NYHA functional class 3 months before enrollment, and smoking status). The benefit of CRT-D therapy as compared with ICD therapy alone among patients with left bundle-branch block and those without left bundle-branch block was assessed by including a term for interaction between treatment and presence or absence of left bundle-branch block in the multivariate Cox models.
Since the assessment of the interaction between QRS morphologic findings and treatment was not prespecified in the original protocol, we also carried out a post-trial landmark analysis (i.e., with the follow-up time beginning on June 23, 2009, which was after trial closure on June 22, 2009). The landmark Cox model was adjusted for the same covariates listed above and for the term for interaction between treatment and presence or absence of left bundle-branch block.
All statistical tests were two-sided, and a P value of less than 0.05 was considered to indicate (Table 1) . During long-term follow-up, 171 of the 1818 patients (9%) crossed over from ICD therapy alone to CRT-D therapy, and 92 (5%) crossed over from CRT-D to ICD therapy alone. Patients who crossed over from ICD to CRT-D therapy had several baseline characteristics that put them at higher risk than those who crossed over from CRT-D to ICD or those who did not cross over, including a higher serum creatinine level, a lower ejection fraction, and larger left ventricular volumes.
CRT-d IN PATIENTS WITH LEFT BUNDLE-BRANCH BLOCK
Kaplan-Meier estimates of death from any cause during the period from enrollment through 7 years of follow-up in the two treatment groups are shown in Figure 2A . The curves diverge at 1 year and continue to have separate paths thereafter, with significantly lower mortality among patients randomly assigned to CRT-D therapy than among those randomly assigned to ICD therapy alone (P = 0.002 by the log-rank test without adjustment). Thus, at 7 years of follow-up, the cumulative rate of death from any cause among patients with left bundle-branch block was 29% in the ICD-only group, as compared with 18% in the CRT-D group. The survival difference corresponded to nine patients who would need to be treated with CRT-D to save one life within 7 years.
The cumulative probability of a nonfatal heartfailure event during 7 years of follow-up was also significantly lower among patients randomly assigned to CRT-D than among those randomly assigned to ICD therapy alone (P<0.001 by the log-rank test without adjustment, for the overall difference during follow-up). The event rates separated at the time of enrollment, and the separa- Survival with CRT in Mild Heart Failure n engl j med nejm.org 5 tion was maintained (Fig. S1 in the Supplementary Appendix). The unadjusted and adjusted hazard ratios for death from any cause and for a nonfatal heartfailure event among patients with and those without left bundle-branch block are shown in Table 2 . For the primary analysis of death from any cause, the adjusted hazard ratio of 0.59 indicated that there was a 41% reduction in the long-term risk of death among patients with left bundle-branch block who were randomly assigned to CRT-D therapy, as compared with those randomly assigned to ICD therapy alone. For the secondary end point of a nonfatal heart-failure event, the adjusted hazard ratio of 0.38 indicated a reduction in risk of 62% with CRT-D ( Table 2) .
The effects of CRT-D therapy on mortality among patients with left bundle-branch block in seven prespecified subgroups are shown in Figure 3 . The survival benefit with CRT-D was consistent in each subgroup analyzed, including patients with ischemic cardiomyopathy and those with nonischemic cardiomyopathy, men and women, and patients with a longer QRS duration (≥150 msec) and those with a shorter QRS duration (<150 msec); there were no significant treatment-by-subgroup interactions. The survival benefit provided by CRT-D in patients with left bundle-branch block was independent of the QRS duration, even when the QRS duration was further categorized into quartiles (Fig. S2 in the Supplementary Appendix).
CRT-d IN PATIENTS WITHOUT LEFT BUNDLE-BRANCH BLOCK
Among patients without left bundle-branch block, Kaplan-Meier survival analysis did not show a significant difference between the two treatment groups in the cumulative probability of death from any cause during the period from enrollment through 7 years of follow-up (P = 0.21 by the logrank test without adjustment) (Fig. 2B) . Similarly, the cumulative probability of a nonfatal heartfailure event during 7 years of follow-up did not differ significantly between the ICD-only group and the CRT-D group (P = 0.58 by the log-rank test without adjustment) (Fig. S3 in the Supplementary Appendix).
Cox proportional-hazards regression modeling consistently showed a lack of benefit associated with CRT-D in patients without left bundlebranch block, with a trend toward an increased risk of death observed only after multivariate adjustment ( Table 2 ). The differential effect of CRT-D on outcomes according to QRS morphologic findings was significant for all end points (P<0.05 for interaction of treatment with QRS morphologic findings, in unadjusted and adjusted analyses) ( Table 2 ). The lack of a survival benefit associated with CRT-D in patients without left bundle-branch block was consistent among those with a longer QRS duration (≥150 msec) or a shorter QRS duration (<150 msec), and among 
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patients with QRS morphologic findings showing right bundle-branch block or intraventricular conduction delay (Fig. S4 in the Supplementary Appendix).
POST-TRIAL ANALYSIS
To further validate the consistency of our findings, we carried out a post-trial landmark analysis (i.e., with the follow-up time beginning after trial closure). The landmark multivariate Cox model showed similar findings: among patients with left bundle-branch block who were alive at the completion of the original trial, treatment with CRT-D was associated with a significant survival benefit during the post-trial follow-up period, as compared with ICD therapy alone (adjusted hazard ratio, 0.58; 95% confidence interval [CI], 0.39 to 0.87; P = 0.009); however, no corresponding benefit was observed in patients without left bundle-branch block (adjusted hazard ratio, 1.31; 95% CI, 0.77 to 2.23; P = 0.32; P = 0.02 for interaction of treatment with QRS morphologic findings).
DISCUSSION
The findings of the present study provide evidence that early intervention with CRT-D is associated with a significant long-term survival benefit in patients with mild heart failure who have left ventricular dysfunction and an ECG pattern showing left bundle-branch block. However, there were no beneficial effects on long-term outcomes in patients without left bundle-branch block. Cardiac-resynchronization therapy (CRT) with or without a defibrillator is associated with reverse remodeling and has been shown to reduce heart-failure symptoms and rates of hospitalization and death among patients with NYHA class III or IV heart failure. [4] [5] [6] [7] MADIT-CRT and the Resynchronization Reverses Remodeling in Systolic Left Ventricular Dysfunction (REVERSE) trial have shown that the echocardiographic and clinical benefit of CRT can be extended to the prevention of heart-failure progression in asymptomatic and mildly symptomatic patients (those in NYHA class I or II) with ischemic and nonischemic cardiomyopathy. 1, 8 In these trials, the mean follow-up time was only 2 to 3 years, raising the question of whether the early benefits of CRT in this population are sustained during long-term follow-up.
The Resynchronization-Defibrillation for Ambulatory Heart Failure Trial (RAFT) showed a reduction in the rate of death from any cause among patients with mild-to-moderate heart failure who were treated with CRT-D. 9 This study, in contrast to ours, also enrolled patients with symptoms of more advanced heart failure (NYHA class III). Thus, the findings of our study extend the RAFT data to patients with only mild heartfailure symptoms (NYHA class I or II) before device implantation. Data from the in-trial phase of MADIT-CRT showed that treatment with CRT-D was associated with a pronounced reduction in the risk of both first and subsequent heart-failure events among patients with left bundle-branch block. There was no detectable effect regarding either of the two end points among patients without left bundle-branch block. 2, 10 The findings from the present study indicate that this treatment interaction was sustained during long-term follow-up. The long-term survival benefit of CRT-D in patients with left bundle-branch block was consistent in each subgroup analyzed, regardless of sex, QRS duration, and ischemic versus nonischemic cause of cardiomyopathy.
The mechanism underlying the differential effect of CRT-D according to QRS morphologic finding in MADIT-CRT is not clear. We previously found that the patients in MADIT-CRT who had an ECG pattern that did not show left bundle-branch block had a significantly lower rate of echocardiographic response to CRT-D and a significant increase in the risk of ventricular tachyarrhythmic events after implantation of a CRT-D device, as compared with patients who had a pattern showing left bundle-branch block. 11 These findings may be due to the fact that the spread of electrical activation in the left ventricular wall in patients without left bundlebranch block is more heterogeneous than in those with left bundle-branch block, 12,13 possibly leading to a pacing-induced discrepancy of the wave front of the electrical activation, which has been shown to be associated with a poor prognosis. 14 In the present study, the lack of a benefit of CRT-D in patients without left bundlebranch block was consistent, regardless of the QRS duration or presence or absence of right bundlebranch block or an intraventricular conduction delay. Thus, at present, our data do not support early intervention with CRT-D in any subset of this population. Our findings are limited by a possible selection bias for the patients who were enrolled in phase 2 of the extended follow-up. It should be noted, however, that nearly all the patients who were lost to follow-up after phase 1 were from the U.S. medical centers that declined to participate in the phase 2 registry, suggesting that the possibility of individual patient bias is limited. It should also be noted that all the analyses in the present study were carried out on an intention-to-treat basis, thereby minimizing the possibility of a survival bias related to crossovers that occurring during or after the in-trial period.
Data from the present study clearly indicate that CRT-D was not beneficial during long-term follow-up in patients without left bundle-branch block who were enrolled in MADIT-CRT. However, the finding regarding a possible harmful effect of CRT-D in this population should be interpreted with caution, since it was obtained only after multivariate adjustment and is therefore sensitive to covariate selection.
In conclusion, our data from the MADIT-CRT long-term follow-up study provide evidence that treatment with CRT-D is associated with a significant long-term survival benefit in patients with mild heart failure who have a left ventricular ejection fraction of 30% or less and left bundle-branch block. However, we did not observe a clinical benefit in patients who had mild heart failure without left bundle-branch block.
Supported by unrestricted research grants from Boston Scientific to the University of Rochester School of Medicine and Dentistry and to the Israeli Association for Cardiovascular Trials.
Disclosure forms provided by the authors are available with the full text of this article at NEJM.org.
